Publications by authors named "Asit Parikh"

Claim this Profile
D
DOCK4 Regulation of Rho GTPases Mediates Pulmonary Vascular Barrier Function.
Pascal Yazbeck, Xavier Cullere, Paul Bennett, Vijay Yajnik, Huan Wang, Asit Parikh

Arterioscler Thromb Vasc Biol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.
Walter Reinisch, Brian Bressler, Rebecca Curtis, Asit Parikh, Huyuan Yang

Inflamm Bowel Dis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials.
Asit Parikh, Kristin Stephens, Eugene Major, Irving Fox, Catherine Milch

Drug Saf· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Maria Rosario, Jonathan L French, Nathanael L Dirks, Serap Sankoh, Asit Parikh

J Crohns Colitis· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
Maria Rosario, Nathanael L Dirks, Catherine Milch, Asit Parikh, Michael Bargfrede

Clin Pharmacokinet· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Maria Rosario, Jonathan L French, Nathanael L Dirks, Serap Sankoh, Asit Parikh

J Crohns Colitis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Jean-Frédéric Colombel, Bruce E Sands, Paul Rutgeerts, William Sandborn, Silvio Danese, Asit Parikh

Gut· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
Maria Rosario, Timothy Wyant, Timothy Leach, Serap Sankoh, Catherine Scholz, Asit Parikh

Clin Drug Investig· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database.
Megan E McAuliffe, Stephan Lanes, Timothy Leach, Asit Parikh, Gerald Faich

Curr Med Res Opin· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Jonathan Goldman, S Gail Eckhardt, Mitesh J Borad, Kelly K Curtis, Manuel Hidalgo, Asit Parikh

Clin Cancer Res· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.
Tim Wyant, Tim Leach, Serap Sankoh, Yuemei Wang, Jonathan Paolino, Asit Parikh

Gut· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Bruce E Sands, Brian G Feagan, Paul Rutgeerts, Jean-Frédéric Colombel, William J Sandborn, Asit Parikh

Gastroenterology· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on 'anti-adhesion therapies and the rule of 3 for rare events'.
Brian G Feagan, Jean-Frederic Colombel, Stephen B Hanauer, Asit Parikh, Paul Rutgeerts

Am J Gastroenterol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.
Catherine Milch, Tim Wyant, Jing Xu, Asit Parikh, Whitney Kent

J Neuroimmunol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, Asit Parikh

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab as induction and maintenance therapy for Crohn's disease.
William J Sandborn, Brian G Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Asit Parikh

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease.
Asit Parikh, Irving Fox, Timothy Leach, Jing Xu, Catherine Scholz

Inflamm Bowel Dis· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.
Asit Parikh, Timothy Leach, Tim Wyant, Catherine Scholz, Serap Sankoh

Inflamm Bowel Dis· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Baumgart review.
Brian G Feagan, Asit Parikh,

Inflamm Bowel Dis· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical research boom in India: opportunism or opportunity?
Asit Parikh

Trop Gastroenterol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.
Brian G Feagan, Gordon R Greenberg, Gary Wild, Richard N Fedorak, Pierre Paré, Asit Parikh

Clin Gastroenterol Hepatol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis